Please assess the completion status of the following clinical trial:

Trial Title: Rasagiline (Azilect) - Neuroprotection for Macula-off Retinal Detachment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Rhegmatogenous retinal detachment~* Central vision affected for less than 72 hours~* Pseudophakic~* Age 18 or over~* Not participating in other clinical trials~* Willing to attend follow-up visits~* Written informed consent~Exclusion Criteria~* Phakic~* Narrow angle glaucoma~* Previous intraocular surgery other than cataract operation~* Retinal disease~* Concurrent treatment with MAO inhibitors~* Pregnancy~* Malignant arterial hypertension~* Liver or kidney failure~* Life-threatening or malignant disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Patients getting perioperative oral treatment with rasagiline (1mg daily) for 7 days
- Control (Type: PLACEBO_COMPARATOR): Patients getting perioperative oral treatment with placebo for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).